{"id":"victoza-liraglutide","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Nausea"},{"rate":"5–10%","effect":"Vomiting"},{"rate":"10–20%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Constipation"},{"rate":"10–15%","effect":"Headache"},{"rate":"variable","effect":"Hypoglycemia (when combined with insulin or sulfonylureas)"}]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite. This results in improved glycemic control and modest weight loss in patients with type 2 diabetes.","oneSentence":"Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:27.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Weight management in obese or overweight patients (at higher doses as Saxenda)"}]},"trialDetails":[{"nctId":"NCT05925959","phase":"NA","title":"Preoperative Weight Loss for Open Abdominal Wall Reconstruction","status":"RECRUITING","sponsor":"Benjamin T. Miller","startDate":"2023-06-19","conditions":"Abdominal Wall Hernia","enrollment":258},{"nctId":"NCT07301437","phase":"PHASE4","title":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"Overweight and Obese Adults","enrollment":120},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT05965908","phase":"PHASE3","title":"Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-01-30","conditions":"Polycystic Ovary","enrollment":150},{"nctId":"NCT05681299","phase":"PHASE4","title":"Effects of GH and Lirglutide on AgRP","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":"Healthy, Growth Hormone Deficiency","enrollment":40},{"nctId":"NCT07304141","phase":"","title":"Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2023-12-20","conditions":"Obesity (Disorder), Child Obesity","enrollment":128},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT02674893","phase":"PHASE4","title":"Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2014-02-04","conditions":"Type 2 Diabetes, Overweight","enrollment":48},{"nctId":"NCT02721888","phase":"PHASE4","title":"Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-07-10","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT03498001","phase":"NA","title":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2018-04-16","conditions":"Type II Diabetes","enrollment":42},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT07374445","phase":"PHASE4","title":"Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-09-01","conditions":"Obesity, Weight Loss, Bariatric Surgery","enrollment":100},{"nctId":"NCT07225816","phase":"PHASE1","title":"Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-07","conditions":"Obesity","enrollment":75},{"nctId":"NCT07094568","phase":"","title":"Tirzepatide vs Liraglutide in Bone","status":"RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2025-05-23","conditions":"Obesity (Disorder)","enrollment":72},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT06283641","phase":"","title":"Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-08","conditions":"Obesity","enrollment":300},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT06482411","phase":"","title":"Risk Factors Affect Weight Loss Outcomes After Treatment.","status":"COMPLETED","sponsor":"E-DA Hospital","startDate":"2024-06-27","conditions":"Weight Regain","enrollment":3602},{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05598008","phase":"","title":"Effects of Glucagon-like-Peptide-1 Analogues on Sexuality","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-11-25","conditions":"Sexual Desire","enrollment":85},{"nctId":"NCT07029009","phase":"PHASE2","title":"Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)","status":"RECRUITING","sponsor":"Mansa","startDate":"2025-05-08","conditions":"Maturity Onset Diabetes of the Young","enrollment":50},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06533527","phase":"PHASE4","title":"Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2024-07-31","conditions":"Diabetes Mellitus, Type 2, Obesity, Gastroparesis","enrollment":69},{"nctId":"NCT04775082","phase":"PHASE3","title":"SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-03-04","conditions":"Obesity","enrollment":78},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT07225829","phase":"PHASE2","title":"A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis","status":"RECRUITING","sponsor":"4Moving Biotech","startDate":"2025-06-17","conditions":"Knee Osteoarthritis, Synovitis of Knee","enrollment":129},{"nctId":"NCT06976619","phase":"PHASE2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-03","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":60},{"nctId":"NCT06836284","phase":"NA","title":"The Evira Study: Additional Support During Anti-Obesity Treatment","status":"NOT_YET_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-10-07","conditions":"Childhood Obesity, Treatment Adherence","enrollment":40},{"nctId":"NCT06171152","phase":"EARLY_PHASE1","title":"Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-01-26","conditions":"Multiple Sclerosis, Long COVID, Long Covid19","enrollment":30},{"nctId":"NCT06439056","phase":"PHASE1","title":"Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D","status":"COMPLETED","sponsor":"Nanexa AB","startDate":"2024-05-27","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT07042672","phase":"","title":"Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2025-07-01","conditions":"Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge","enrollment":80},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT05221229","phase":"","title":"Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Birmingham","startDate":"2022-04-17","conditions":"Atrial Fibrillation, Recurrence, Overweight and Obesity","enrollment":29},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT03260881","phase":"PHASE4","title":"Liraglutide Effects on Epicardial Fat Inflammatory Genes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-09-01","conditions":"Type2 Diabetes, Coronary Artery Disease","enrollment":38},{"nctId":"NCT05419856","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee","status":"COMPLETED","sponsor":"4Moving Biotech","startDate":"2022-08-09","conditions":"Knee Osteoarthritis","enrollment":34},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06742710","phase":"PHASE4","title":"Liraglutide Treatment in Obese Infertile PCOS Women","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-05-22","conditions":"PCOS, Obesity, Infertility","enrollment":890},{"nctId":"NCT04575844","phase":"PHASE4","title":"Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2020-11-01","conditions":"Metabolic Syndrome","enrollment":80},{"nctId":"NCT02516657","phase":"PHASE3","title":"Liraglutide in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-05","conditions":"Type 1 Diabetes","enrollment":5},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT06865365","phase":"PHASE4","title":"Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-05-01","conditions":"Obesity, Adolescent","enrollment":72},{"nctId":"NCT02944500","phase":"PHASE4","title":"Saxenda: Underlying Mechanisms and Clinical Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Obesity","enrollment":28},{"nctId":"NCT03158805","phase":"PHASE2","title":"Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2017-04-26","conditions":"Bipolar Disorder, Obesity","enrollment":60},{"nctId":"NCT04881110","phase":"PHASE4","title":"Liraglutide and Peripheral Artery Disease","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-02-01","conditions":"Type 2 Diabetes, Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT06400615","phase":"PHASE2","title":"Study That Tests AD109 in Patients Taking GLP-1 Drugs","status":"COMPLETED","sponsor":"Apnimed","startDate":"2024-05-20","conditions":"OSA","enrollment":40},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT06818292","phase":"NA","title":"Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","status":"COMPLETED","sponsor":"Nils Opel","startDate":"2024-10-21","conditions":"Healthy","enrollment":10},{"nctId":"NCT05268237","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Biolingus","startDate":"2023-04-25","conditions":"Diabete Type 2","enrollment":15},{"nctId":"NCT06500130","phase":"NA","title":"Effects of Liraglutide on Body Surface Gastric Mapping","status":"COMPLETED","sponsor":"Alimetry","startDate":"2024-05-30","conditions":"Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome","enrollment":22},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05794581","phase":"PHASE1","title":"A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2023-03-21","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT06726577","phase":"PHASE1, PHASE2","title":"TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"Talengen Institute of Life Sciences, Shenzhen, P.R. China.","startDate":"2024-12-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":60},{"nctId":"NCT06361238","phase":"PHASE3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-19","conditions":"Delirium, Postoperative","enrollment":260},{"nctId":"NCT06720246","phase":"","title":"Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity","status":"RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2024-06-26","conditions":"Obesity and Overweight","enrollment":50},{"nctId":"NCT04883346","phase":"PHASE2","title":"Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2021-06-21","conditions":"Obesity, Status Post Sleeve Gastrectomy","enrollment":34},{"nctId":"NCT06686134","phase":"","title":"Comprehensive Clinical Evaluation Study of GLP-1RA","status":"RECRUITING","sponsor":"LI YAN","startDate":"2024-07-01","conditions":"T2DM","enrollment":492},{"nctId":"NCT03555994","phase":"PHASE2","title":"A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-31","conditions":"Type 2 Diabetes Mellitus","enrollment":51},{"nctId":"NCT06581120","phase":"","title":"GLP_1 RA Ultrasound Study","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-07-08","conditions":"Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration","enrollment":100},{"nctId":"NCT04199728","phase":"PHASE1, PHASE2","title":"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-10-18","conditions":"Opiate Substitution Treatment, Opioid-Related Disorders","enrollment":27},{"nctId":"NCT03115424","phase":"PHASE3","title":"Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-06-22","conditions":"Obesity","enrollment":46},{"nctId":"NCT04683237","phase":"PHASE2, PHASE3","title":"Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia","status":"WITHDRAWN","sponsor":"Xiaojun Chen","startDate":"2021-03-20","conditions":"Atypical Endometrial Hyperplasia, Obese, Fertility Issues","enrollment":""},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT06099067","phase":"","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-15","conditions":"Type 2 Diabetes Mellitus","enrollment":239990},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT03036800","phase":"PHASE4","title":"Saxenda in Obesity Services (STRIVE Study)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2017-11-28","conditions":"Obesity, Weight Loss, Diabetes Mellitus","enrollment":392},{"nctId":"NCT04763564","phase":"PHASE2","title":"Efficacy of Liraglutide Therapy in Patients With IPAA","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-22","conditions":"Pouchitis, Irritable Pouch Syndrome","enrollment":8},{"nctId":"NCT02403284","phase":"PHASE4","title":"The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-03","conditions":"Insulin Resistance","enrollment":97},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03500484","phase":"EARLY_PHASE1","title":"Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-06-06","conditions":"Obesity, Childhood, Neural Development","enrollment":13},{"nctId":"NCT06501326","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-11-01","conditions":"Non-alcoholic Fatty Liver Disease, Obesity","enrollment":102},{"nctId":"NCT03856047","phase":"PHASE2","title":"Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-03-01","conditions":"Overweight, Obesity","enrollment":706},{"nctId":"NCT03885297","phase":"","title":"3mg Liraglutide for Overweight or Obesity","status":"COMPLETED","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust","startDate":"2019-01-18","conditions":"Overweight, Obesity, Infertility, Female","enrollment":43},{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT06438146","phase":"PHASE4","title":"LIROH - Liraglutide for Obesity in HIV","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-05-02","conditions":"Obesity, HIV Infections","enrollment":40},{"nctId":"NCT04311411","phase":"PHASE1","title":"A Study of Tirzepatide in Overweight and Very Overweight Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-24","conditions":"Obesity, Overweight","enrollment":114},{"nctId":"NCT06408532","phase":"PHASE4","title":"The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT04666987","phase":"","title":"A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":359},{"nctId":"NCT02953665","phase":"PHASE2","title":"Safety and Efficacy of Liraglutide in Parkinson's Disease","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-04-03","conditions":"Parkinson Disease","enrollment":63},{"nctId":"NCT03672812","phase":"PHASE3","title":"The Use of Liraglutide in Brain Death","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2018-09-01","conditions":"Brain Death","enrollment":50},{"nctId":"NCT02777073","phase":"NA","title":"Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-03-01","conditions":"Type 1 Diabetes","enrollment":43},{"nctId":"NCT05390307","phase":"NA","title":"Obesity Treatment to Improve Diabetes","status":"COMPLETED","sponsor":"Dasman Diabetes Institute","startDate":"2023-04-01","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT05136287","phase":"","title":"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2022-02-01","conditions":"Weight Loss, Diabetes Mellitus, Type 2, Quality of Life","enrollment":140},{"nctId":"NCT03993132","phase":"","title":"A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":26774},{"nctId":"NCT01509742","phase":"PHASE1","title":"Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":19},{"nctId":"NCT06120556","phase":"","title":"Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2023-06-10","conditions":"Diabetes Mellitus, Type 2","enrollment":130},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01722240","phase":"PHASE3","title":"Liraglutide in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":69},{"nctId":"NCT06217848","phase":"EARLY_PHASE1","title":"The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2022-11-28","conditions":"Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity","enrollment":50},{"nctId":"NCT06201819","phase":"PHASE4","title":"Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery","status":"COMPLETED","sponsor":"Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca","startDate":"2022-12-18","conditions":"Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid","enrollment":37},{"nctId":"NCT01722266","phase":"PHASE3","title":"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":72}],"_emaApprovals":[],"_faersSignals":[{"count":416,"reaction":"NAUSEA"},{"count":260,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":165,"reaction":"DIARRHOEA"},{"count":145,"reaction":"DECREASED APPETITE"},{"count":138,"reaction":"PANCREATITIS"},{"count":129,"reaction":"VOMITING"},{"count":98,"reaction":"HEADACHE"},{"count":87,"reaction":"INJECTION SITE HAEMATOMA"},{"count":74,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":73,"reaction":"INJECTION SITE PAIN"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza"],"phase":"marketed","status":"active","brandName":"Victoza (liraglutide)","genericName":"Victoza (liraglutide)","companyName":"Zealand University Hospital","companyId":"zealand-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients (at higher doses as Saxenda).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}